Lansing’s XG Sciences Partners with Perpetuus Advance Materials to License, Commercialize Graphene

XG Sciences in Lansing, which designs and manufactures graphene nanoplatelets and advanced materials containing graphene nanoplatelets, has entered into a commercialization and license agreement with Perpetuus Advanced Materials in Ammanford, South Wales, which produces dispersible, surface-modified graphene to optimize performance in matrices and end-use markets.
335
tires
XG Sciences and Perpetuus Advanced Materials have partnered to use graphene nanoplatelets. The companies will initially work with tires. // Image courtesy of XG Sciences

XG Sciences in Lansing, which designs and manufactures graphene nanoplatelets and advanced materials containing graphene nanoplatelets, has entered into a commercialization and license agreement with Perpetuus Advanced Materials in Ammanford, South Wales, which produces dispersible, surface-modified graphene to optimize performance in matrices and end-use markets.

Graphene is a single layer of carbon atoms and was first isolated and characterized in 2004. It is harder than diamonds, lighter and stronger than steel, and conducts electricity better than copper.

Graphene nanoplatelets are particles consisting of multiple layers of graphene with unique capabilities for energy storage, thermal conductivity, electrical conductivity, barrier properties, lubricity, and the ability to impart physical property improvements when incorporated into plastics, metals, or other matrices.

“We have been working with Perpetuus in various commercial and development efforts for the past several years,” says Philip Rose, CEO of XG Sciences. “This Agreement represents a key milestone in the commercial adoption of graphene and establishes XG Sciences and Perpetuus as marque players in the supply of graphene for use in tire elastomers and other applications.”

Under the agreements, Perpetuus will locate at least one of its plasma-based surfaces-modification production plants in the U.S. near one of the XG Sciences’ graphene nanoplatelet production facilities. The collaboration is for both product development and high-volume commercial supply.

“XG Sciences is a well-known leader in the graphene field and is an ideal choice with whom to partner to bring our technology to this important market,” says John Buckland, CEO of Perpetuus.

The companies will initially focus on elastomers with an emphasis on tires and related applications but may expand the relationship over time.

Facebook Comments